Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Q1 2026 earnings due May 6 after market close — analysts expect EPS of $0.975 and revenue of $475.6 million, with a conference call scheduled for 4:30 PM ET that day.
• Sarepta's last quarter was marked by a large earnings miss (reported -$3.58 EPS vs. -$0.87 expected), revenue down 32.7% year‑over‑year, and negative return on equity and net margin, underscoring recent volatility and operational challenges.
• The market consensus is a Hold with a $32.63 price target and mixed analyst sentiment (9 Buys, 13 Holds, 6 Sells); the company has a market cap of about $2.22 billion and a 12‑month trading range of $10.41–$64.80.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.9750 per share and revenue of $475.5980 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business's quarterly revenue was down 32.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.90 earnings per share. On average, analysts expect Sarepta Therapeutics to post $3 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $21.06 on Wednesday. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. The business's 50 day moving average is $19.48 and its two-hundred day moving average is $20.33. The company has a market cap of $2.22 billion, a P/E ratio of -2.50, a P/E/G ratio of 0.32 and a beta of 0.29. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $64.80.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SRPT shares. Wedbush lifted their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an "outperform" rating in a report on Thursday, March 26th. Oppenheimer reissued an "outperform" rating and set a $37.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Royal Bank Of Canada lifted their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a "sector perform" rating in a report on Tuesday, April 7th. Citigroup lifted their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a "sell" rating in a report on Thursday, March 26th. Finally, Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $32.63.

Insider Buying and Selling

In related news, Director Stephen Mayo sold 7,239 shares of the business's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director owned 1,765 shares of the company's stock, valued at $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans boosted its stake in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock valued at $396,000 after buying an additional 744 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sarepta Therapeutics by 1.8% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company's stock valued at $829,000 after buying an additional 758 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Sarepta Therapeutics by 3.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 24,620 shares of the biotechnology company's stock valued at $530,000 after buying an additional 896 shares in the last quarter. Ancora Advisors LLC boosted its stake in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after buying an additional 1,000 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Sarepta Therapeutics by 4.2% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,942 shares of the biotechnology company's stock valued at $558,000 after buying an additional 1,057 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.